Boru Jin1, Huayan Liu2. 1. Department of Neurology, First Affiliated Hospital, China Medical University, No. 155, North Nanjing Street, Shenyang, 110001, People's Republic of China. 2. Department of Neurology, First Affiliated Hospital, China Medical University, No. 155, North Nanjing Street, Shenyang, 110001, People's Republic of China. liuhuayancmu@163.com.
Abstract
OBJECTIVE: To assess the comparative efficacy and safety of both pharmacological and non-pharmacological therapies for the behavioral and psychological symptoms of dementia, using direct and indirect evidence from randomized data. METHOD: A systematic review and Bayesian network meta-analysis was conducted on only randomized controlled trials (RCTs) of all the available interventions for BPSD. RCTs were selected from Pubmed, EMBASE, the Cochrane library, and CINAHL. The efficacy outcomes were Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory (CMAI). The outcomes of safety were total adverse events (AEs), diarrhea, dizziness, headache, falls, nausea, vomiting, and cerebrovascular diseases. RESULT: 146 RCTs comprising 44,873 patients with BPSD were included in this study. On NPI, aripiprazole (MD - 3.65, 95% credible interval (CrI) = - 6.92 to - 0.42), escitalopram (MD - 6.79, 95% CrI - 12.91 to - 0.60), donepezil (MD - 1.45, 95% CrI - 2.70 to - 0.20), galantamine (MD - 1.80, 95% CrI - 3.29 to - 0.32), memantine (MD - 2.14, 95% CrI - 3.46 to - 0.78), and risperidone (MD - 3.20, 95% CrI - 6.08 to - 0.31) were superior to placebo. On CMAI, aripiprazole (MD - 4.00, 95% CrI - 7.39 to - 0.54) and risperidone (MD - 2.58, 95% CrI - 5.20 to - 0.6) showed superiority to placebo. On the risk of total AEs, donepezil (OR 1.27, 95% CrI 1.07-1.50), galantamine (OR 1.91, 95% CrI 1.58-2.36), risperidone (OR 1.47, 95% CrI 1.13-1.97), and rivastigmine (OR 2.02, 95% CrI 1.53-2.70) owned higher risk than placebo. CONCLUSION: Pharmacological therapies should be the first choice for BPSD. Aripiprazole, haloperidol, quetiapine, and risperidone of antipsychotics showed the significant efficacy, while memantine, galantine, and donepezil may provide the modest effectiveness. The safety of all was thought to be acceptable.
OBJECTIVE: To assess the comparative efficacy and safety of both pharmacological and non-pharmacological therapies for the behavioral and psychological symptoms of dementia, using direct and indirect evidence from randomized data. METHOD: A systematic review and Bayesian network meta-analysis was conducted on only randomized controlled trials (RCTs) of all the available interventions for BPSD. RCTs were selected from Pubmed, EMBASE, the Cochrane library, and CINAHL. The efficacy outcomes were Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory (CMAI). The outcomes of safety were total adverse events (AEs), diarrhea, dizziness, headache, falls, nausea, vomiting, and cerebrovascular diseases. RESULT: 146 RCTs comprising 44,873 patients with BPSD were included in this study. On NPI, aripiprazole (MD - 3.65, 95% credible interval (CrI) = - 6.92 to - 0.42), escitalopram (MD - 6.79, 95% CrI - 12.91 to - 0.60), donepezil (MD - 1.45, 95% CrI - 2.70 to - 0.20), galantamine (MD - 1.80, 95% CrI - 3.29 to - 0.32), memantine (MD - 2.14, 95% CrI - 3.46 to - 0.78), and risperidone (MD - 3.20, 95% CrI - 6.08 to - 0.31) were superior to placebo. On CMAI, aripiprazole (MD - 4.00, 95% CrI - 7.39 to - 0.54) and risperidone (MD - 2.58, 95% CrI - 5.20 to - 0.6) showed superiority to placebo. On the risk of total AEs, donepezil (OR 1.27, 95% CrI 1.07-1.50), galantamine (OR 1.91, 95% CrI 1.58-2.36), risperidone (OR 1.47, 95% CrI 1.13-1.97), and rivastigmine (OR 2.02, 95% CrI 1.53-2.70) owned higher risk than placebo. CONCLUSION: Pharmacological therapies should be the first choice for BPSD. Aripiprazole, haloperidol, quetiapine, and risperidone of antipsychotics showed the significant efficacy, while memantine, galantine, and donepezil may provide the modest effectiveness. The safety of all was thought to be acceptable.
Entities:
Keywords:
Behavioral and psychological symptoms of dementia; Dementia; Network meta-analysis; Non-pharmacological therapy; Pharmacological therapy; Systematic review
Authors: C A C Coupland; P Dhiman; G Barton; R Morriss; A Arthur; T Sach; J Hippisley-Cox Journal: Health Technol Assess Date: 2011-08 Impact factor: 4.014
Authors: Sofia Dias; Nicky J Welton; Alex J Sutton; Deborah M Caldwell; Guobing Lu; A E Ades Journal: Med Decis Making Date: 2013-07 Impact factor: 2.583
Authors: Eleni Poptsi; Magda Tsolaki; Sverre Bergh; Bruno Mario Cesana; Alfonso Ciccone; Andrea Fabbo; Giovanni B Frisoni; Lutz Frölich; Sara Lavolpe; Anna Giulia Guazzarini; Jacques Hugon; Sara Fascendini; Carlo Alberto Defanti Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schroeder; Katharina Buerger; Claudia Müller; Bianca Dorn; Oliver Goldhardt; Janine Diehl-Schmid; Hans Förstl; Werner Steimer; Timo Grimmer Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810
Authors: Jennifer A Watt; Zahra Goodarzi; Areti Angeliki Veroniki; Vera Nincic; Paul A Khan; Marco Ghassemi; Yuan Thompson; Yonda Lai; Victoria Treister; Andrea C Tricco; Sharon E Straus Journal: BMC Geriatr Date: 2020-06-16 Impact factor: 3.921